|
| Primary information |
|---|
| ID | 15827 |
| Therapeutic ID | Th1632 |
| Protein Name | Inolimomab |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385] |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | Inolimomab is a murine monoclonal antibody targeting CD-25, also known as the alpha subunit of the interleukin-2 receptor. [L39010] The binding of this antibody to CD-25 blocks the signaling of interleukin-2, preventing clonal expansion of T-cells. The resulting immunosuppressive effect appears to provide a similar benefit in patients with steroid-resistant graft vs host disease to anti-thymocyte globulin.[A241380] |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | Immunosuppressive Agents |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Interleukin-2 receptor subunit alpha |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |